Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
Globe Newswire•11/11/2026•08:53 ET
0
Key Highlights
- ➤Tempest exercises exclusive global ex-China license for Senlang’s CD7-targeted lentiviral platform
- ➤TPST-4903 studied in 13 heavily pretreated relapsed/refractory multiple myeloma patients
- ➤Preliminary clinical activity and tolerability observations support further TPST-4903 evaluation
- ➤TPST-4903 targets BCMA and GPRC5D using CD7-targeted lentiviral delivery
- ➤Detailed DELIVER-1 Phase 1 results expected at a major scientific conference
Expert Statements
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“We are encouraged by the emerging clinical data from the ongoing DELIVER-1 Phase 1 dose-escalation study of TPST-4903, which includes multiple myeloma patients with a substantial unmet need for new treatment options, such as those with extramedullary disease and those previously treated with CAR-T therapy.”
Matt Angel, President and Chief Executive Officer of Tempest Therapeutics
“We look forward to sharing the detailed results with the scientific community.”
Dr. Angel, President and Chief Executive Officer of Tempest Therapeutics
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Dr. Angel, President and Chief Executive Officer of Tempest Therapeutics
“We continue to believe that these complementary platforms provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases.”
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates
-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure
Get started
Create a free account to read the full story.